Undisclosed PEP Candidates
Various Endocrine and Metabolic Disorders
DiscoveryActive discovery pursuits
Key Facts
Indication
Various Endocrine and Metabolic Disorders
Phase
Discovery
Status
Active discovery pursuits
Company
About MBX Biosciences
MBX Biosciences is focused on developing innovative peptide therapeutics for underserved endocrine and metabolic markets. Enabled by its proprietary PEP platform technology, the company is advancing a pipeline of candidates, with its lead program, canvuparatide, showing positive Phase 1 data and having completed a Phase 2 trial in hypoparathyroidism. The company's mission is to help patients live fuller, healthier lives by translating leading-edge peptide science into convenient, transformative medicines.
View full company profile